ImmunoCellular Therapeutics (IMUC) 10-K 10 Mar 15 2014 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2014	Feb. 27, 2015	Jun. 30, 2014
Document And Entity Information [Abstract]
Entity Registrant Name	ImmunoCellular Therapeutics, Ltd.
Entity Central Index Key	822411
Document Type	10-K
Document Period End Date	31-Dec-14
Amendment Flag	FALSE
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY
Trading Symbol	IMUC
Current Fiscal Year End Date	-19
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Public Float			$67,606,518
Entity Common Stock, Shares Outstanding		90,254,823

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2014	Dec. 31, 2013
Current assets:
Cash and cash equivalents	$23,222,296	$27,646,351
Other assets	1,219,873	763,299
Total current assets	24,442,169	28,409,650
Property and equipment, net	47,365	66,442
Deferred financing costs	-105,563
Other assets	583,464	464,585
Total assets	25,178,561	28,940,677
Current liabilities:
Accounts payable	322,002	861,026
Accrued compensation and benefits	334,527	357,265
Accrued liabilities	632,670	183,982
Total current liabilities	1,289,199	1,402,273
Warrant Liability	597,719	1,064,810
Commitments and contingencies (Note 5)
Shareholders’ equity:
Common stock, $0.0001 par value; 149,000,000 shares authorized; 63,604,823 and 57,542,231 shares issued and outstanding as of December 31, 2014 and December 31, 2013, respectively	6,360	5,754
Additional paid-in capital	84,632,209	78,437,233
Accumulated deficit	-61,346,926	-51,969,393
Total shareholders’ equity	23,291,643	26,473,594
Total liabilities and shareholders’ equity	$25,178,561	$28,940,677

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Statement Of Financial Position [Abstract]
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	149,000,000	149,000,000
Common stock, shares issued	63,604,823	57,542,231
Common stock, shares outstanding	63,604,823	57,542,231

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Expenses:
Research and development	$5,969,182	$5,339,716	$7,711,233
Stock based compensation	654,260	724,212	496,007
General and administrative	3,235,099	3,396,391	3,619,291
Total expenses	9,858,541	9,460,319	11,826,531
Loss before other income (expense) and income taxes	-9,858,541	-9,460,319	-11,826,531
Interest income	13,917	17,345	8,609
Financing expense	-62,683		-397,294
Change in fair value of warrant liability	529,774	642,411	-2,279,923
Loss before income taxes	-9,377,533	-8,800,563	-14,495,139
Net loss	($9,377,533)	($8,800,563)	($14,495,139)
Loss per share	($0.16)	($0.16)	($0.35)
Weighted average number of shares basic and diluted	59,915,086	54,281,189	41,797,048

Consolidated_Statements_of_Sha

Consolidated Statements of Shareholders' Equity (Deficit) (USD $)	Total	Common Stock and Warrants Issued for Cash 1.1 Per Share	Common Stock and Warrants Issued for Cash 2.1 Per Share	Common Stock Issued For License Rights 2.41 Per Share	Common Stock	Common Stock	Common Stock	Common Stock	Additional Paid-in Capital	Additional Paid-in Capital	Additional Paid-in Capital	Additional Paid-in Capital	Accumulated Deficit
						Common Stock and Warrants Issued for Cash 1.1 Per Share	Common Stock and Warrants Issued for Cash 2.1 Per Share	Common Stock Issued For License Rights 2.41 Per Share		Common Stock and Warrants Issued for Cash 1.1 Per Share	Common Stock and Warrants Issued for Cash 2.1 Per Share	Common Stock Issued For License Rights 2.41 Per Share
Beginning Balance at Dec. 31, 2011	$3,232,060				$2,861				$31,902,890				($28,673,691)
Balance, shares at Dec. 31, 2011					28,613,984
Common stock and warrants issued for cash, net of offering costs		9,271,370	19,359,553			949	1,000			9,270,421	19,358,553
Common stock and warrants issued for cash, net of offering costs, shares						9,489,436	10,000,000
Exercise of warrants	3,201,920				230				3,201,690
Exercise of warrants, shares					2,295,334
Reclassification of warratn liability upon exercise	1,981,743								1,981,743
Cashless exercise of warrants					29				-29
Cashless exercise of warrants shares					288,973
Cashless exercise of stock options					79				-79
Cashless exercise of stock options, shares					792,018
Restricted stock vested, shares					1,251
Stock based compensation	496,007								496,007
Exercise of stock options	20,500				2				20,498
Exercise of stock options, shares	1,285,384				20,000
Net loss	-14,495,139												-14,495,139
Ending Balance at Dec. 31, 2012	23,068,014				5,150				66,231,694				-43,168,830
Ending Balance, shares at Dec. 31, 2012					51,500,996
Exercise of warrants	6,176,336				344				6,175,992
Exercise of warrants, shares					3,441,551
Cashless exercise of warrants					3				-3
Cashless exercise of warrants shares					31,155
Cashless exercise of stock options					15				-15
Cashless exercise of stock options, shares					149,385
Stock based compensation	724,215				3				724,212
Exercise of stock options	324,517				53				324,464
Exercise of stock options, shares	829,702				528,702
Net loss	-8,800,563												-8,800,563
Common stock issued for license rights				75,014				17				74,997
Common stock issued for license rights, shares								28,300
Common stock issued through controlled equity offering	4,906,061				169				4,905,892
Common stock issued through controlled equity offering, shares					1,862,142
Ending Balance at Dec. 31, 2013	26,473,594				5,754				78,437,233				-51,969,393
Ending Balance, shares at Dec. 31, 2013					57,542,231
Cashless exercise of stock options					3				-3
Cashless exercise of stock options, shares					28,473
Stock based compensation	654,260								654,260
Exercise of stock options	1,045,000				95				1,044,905
Exercise of stock options, shares	624,047				950,000
Net loss	-9,377,533												-9,377,533
Common stock issued through controlled equity offering	4,496,322				508				4,495,814
Common stock issued through controlled equity offering, shares					5,084,119
Ending Balance at Dec. 31, 2014	$23,291,643				$6,360				$84,632,209				($61,346,926)
Ending Balance, shares at Dec. 31, 2014					63,604,823

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Shareholders' Equity (Deficit) (Parenthetical) (USD $)	1 Months Ended		12 Months Ended
	Jan. 31, 2012	Oct. 31, 2012	Dec. 31, 2013	Dec. 31, 2014
Common Stock and Warrants Issued for Cash 1.1 Per Share
Common stock and warrants issued for cash per share	$1.10
Common Stock and Warrants Issued for Cash 2.1 Per Share
Common stock and warrants issued for cash per share		$2.10
Common Stock Issued For License Rights 2.41 Per Share
Common stock issued for licensing rights per share			$2.41
Offer and Sale
Common stock issued through controlled equity offering average, per share			$2.82	$0.92

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Cash flows from operating activities:
Net loss	($9,377,533)	($8,800,563)	($14,495,139)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	47,656	50,402	45,823
(Gain) loss on disposal of assets	-4	3,817
Change in fair value of warrant liability	-529,774	-642,411	2,279,923
Financing expense	62,683		397,294
Stock-based compensation	654,260	724,212	496,007
Changes in assets and liabilities:
Other assets	-575,453	-426,640	-623,538
Accounts payable	-644,587	128,175	-401,090
Accrued liabilities	425,950	175,791	-79,293
Net cash used in operating activities	-9,936,802	-8,787,217	-12,380,013
Cash flows from investing activities:
Purchase of property and equipment	-28,975	-44,372	-9,828
Proceeds from sale of property and equipment	400
Net cash used in investing activities	-28,575	-44,372	-9,828
Cash flows from financing activities:
Proceeds from exercise of stock options	1,045,000	324,517	20,500
Proceeds from exercise of warrants		5,030,677	3,201,918
Proceeds from issuance of common stock and warrants net of offering costs	4,496,322	4,906,078	28,730,923
Net cash provided by financing activities	5,541,322	10,261,272	31,953,341
Increase (decrease) in cash and cash equivalents	-4,424,055	1,429,683	19,563,500
Cash and cash equivalents, beginning of period	27,646,351	26,216,668	6,653,168
Cash and cash equivalents, end of period	23,222,296	27,646,351	26,216,668
Supplemental non-cash financing disclosures:
Warrant liability converted to additional paid-in capital		1,145,659	1,981,745
Common stock issued for license rights		75,000
Deposits used to acquire property and equipment			35,882
Deferred offering costs	$105,563

Nature_of_Organization_Planned

Nature of Organization (Planned Principal Operations Have Not Commenced)	12 Months Ended
	Dec. 31, 2014
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Nature of Organization (Planned Principal Operations Have Not Commenced)	1	Nature of Organization (Planned Principal Operations Have Not Commenced)
	ImmunoCellular Therapeutics, Ltd. (the Company) is seeking to develop and commercialize new therapeutics to fight cancer using the immune system. These consolidated financial statements include the Company’s wholly owned subsidiaries, ImmunoCellular Bermuda, Ltd. in Bermuda and ImmunoCellular Therapeutics (Ireland) Limited and ImmunoCellular Therapeutics (Europe) Limited in Ireland, that were formed during 2014.
	The Company has been primarily engaged in the acquisition of certain intellectual property, together with development of its product candidates and the recent clinical testing activities for one of its vaccine product candidates, and has not generated any recurring revenues. The Company’s lead product candidate, ICT-107, is in Phase II clinical development. The Company has two other product candidates, ICT-140 and ICT-121, both with investigational new drug (IND) applications active at the US Food and Drug Administration (FDA). Currently, the Company has suspended development of ICT-140 until the Company has secured a partner or sufficient financial resources to commence the ICT-107 phase III program.  Additionally, the Company has acquired the rights to technology for the development of certain stem cell immunotherapies for the treatment of cancer.  The Company has incurred operating losses and, as of December 31, 2014, the Company had an accumulated deficit of $61,346,926. The Company expects to incur significant research, development and administrative expenses before any of its products can be launched and recurring revenues generated.
	The Company's activities are subject to significant risks and uncertainties, including the failure of any of the Company's product candidates to achieve clinical success or to obtain regulatory approval.  Additionally, it is possible that other companies with competing products and technology might obtain regulatory approval ahead of the Company.  The Company will need significant amounts of additional funding in order to complete the development of any of its product candidates and the availability and terms of such funding cannot be assured.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2	Summary of Significant Accounting Policies
	Principles of Consolidation – The accompanying consolidated financial statements include the accounts of the Company and its subsidiaries.  All significant intercompany balances and transactions have been eliminated in consolidation.
	Liquidity —As of December 31, 2014, the Company had working capital of $23,152,970, compared to working capital of $27,007,377 as of December 31, 2013. The estimated cost of completing the development of any of our current vaccine product candidates and of obtaining all required regulatory approvals to market any of those product candidates is substantially greater than the amount of funds we currently have available. However, we believe that our existing cash balances are sufficient for our currently planned level of operations for at least the next twelve months from the date of filing of this Annual Report on Form 10-K, although there is no assurance that such proceeds will be sufficient for this purpose.
	Cash and cash equivalents—The Company considers all highly liquid instruments with an original maturity of 90 days or less when purchased to be cash equivalents. As of December 31, 2014 and December 31, 2013, the Company had $10,427,810      and $25,913,893, respectively, of certificates of deposit. The Company places its cash and cash equivalents with various banks in order to maintain FDIC insurance on all of its investments.
	Property and Equipment—Property and equipment are stated at cost and depreciated using the straight-line methods based on the estimated useful lives (generally three to five years) of the related assets. Computer and computer equipment are depreciated over three years. Management continuously monitors and evaluates the realizability of recorded long-lived assets to determine whether their carrying values have been impaired. The Company records impairment losses on long-lived assets used in operations when events and circumstances indicate that the assets might be impaired and the nondiscounted cash flows estimated to be generated by those assets are less than the carrying amount of those assets. Any impairment loss is measured by comparing the fair value of the asset to its carrying amount. Repairs and maintenance costs are expensed as incurred.
	Research and Development Expenses—Research and development expenses consist of costs incurred for direct research and development and are expensed as incurred.
	Stock Based Compensation—The Company records the cost for all share-based payment transactions in the Company’s consolidated financial statements.
	Fair value was estimated at the date of grant using the following assumptions:
			Year			Year			Year
			Ended			Ended			Ended
			December 31,			December 31,			December 31,
			2014			2013			2012
	Risk-free interest rate			2.18	%		1.64	%		0,49	%
	Expected dividend yield			None			None			None
	Expected life			5.47 years			5.21 years			4.40 years
	Expected volatility			95.3	%		90.58	%		66.1	%
	Expected forfeitures			0	%		0	%		0	%
	The weighted-average grant-date fair value of options granted during the year ended December 31, 2014, 2013 and 2012 was $0.96     , $1.89 and $1.29, respectively.
	The risk-free interest rate used is based on the implied yield currently available in U.S. Treasury securities at maturity with an equivalent term. The Company has not declared or paid any dividends and does not currently expect to do so in the future. The expected term of options represents the period that our stock-based awards are expected to be outstanding and was determined based on projected holding periods for the remaining unexercised shares. Consideration was given to the contractual terms of our stock-based awards, vesting schedules and expectations of future employee behavior. For the year ended December 31, 2014, the expected volatility is based upon the historical volatility of the Company’s common stock. Forfeitures have been estimated to be nil.
	The Company’s stock price volatility and option lives involve management’s best estimates, both of which impact the fair value of the option calculated and, ultimately, the expense that will be recognized over the life of the option.
	When options are exercised, our policy is to issue previously unissued shares of common stock to satisfy share option exercises. As of December 31, 2014, the Company had 56,491,509      shares of authorized but unissued common stock. As of December 31, 2014, the Company had 5,835,731 shares of common stock reserved for its stock option plan.
	No tax benefits were attributed to the stock-based compensation expense because a valuation allowance was maintained for all net deferred tax assets.
	Income Taxes—The Company accounts for federal and state income taxes under the liability method, with a deferred tax asset or liability determined based on the difference between the financial statement and tax basis of assets and liabilities, as measured by the enacted tax rates. The Company’s provision for income taxes represents the amount of taxes currently payable, if any, plus the change in the amount of net deferred tax assets or liabilities. A valuation allowance is provided against net deferred tax assets if recoverability is uncertain on a more likely than not basis. As of December 31, 2014 and 2013, the Company fully reserved its deferred tax assets. The Company recognizes in its consolidated financial statements the impact of an uncertain tax position if the position will more likely than not be sustained upon examination by a taxing authority, based on the technical merits of the position. The Company’s policy is to recognize interest related to unrecognized tax benefits as interest expense and penalties as operating expenses. As of December 31, 2014, the Company had no unrecognized tax benefits and as such, no liability, interest or penalties were required to be recorded.  The Company does not expect this to change significantly in the next twelve months.  The Company has determined that its main taxing jurisdictions are the United States of America and the State of California.  The Company is not currently under examination by any taxing authority nor has it been notified of a pending examination. The Company’s tax returns are generally no longer subject to examination for the years before December 31, 2010 for the state and December 31, 2011 for the federal taxing authority.
	During the fourth quarter of 2014, the Company licensed the non-U.S. rights to a significant portion of its intellectual property to its Bermuda-based subsidiary for approximately $11.0 million. The fair value of the intellectual property rights was determined by an independent third party. The proceeds from this sale represent a gain for U.S. tax purposes and are offset by current year losses and net operating loss carryforwards. However, the Internal Revenue Service, or the IRS, or the California Franchise Tax Board, or the CFTB, could challenge the valuation of the intellectual property rights and assess a greater valuation, which would require the Company to utilize a portion, or all, of its available net operating losses. If an IRS or a CFTB valuation exceeds the available net operating losses, the Company would incur additional income taxes. The Company’s ability to use its net operating losses is subject to the limitations of IRS Section 382, as well as expiration of federal and state net operating loss carryforwards.
	Fair Value of Financial Instruments—The carrying amounts reported in the balance sheets for cash, cash equivalents, and accounts payable approximate their fair values due to their quick turnover. The fair value of warrant liability is estimated using the Binomial Lattice option valuation model.
	Fair value for financial reporting is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.  The Company utilizes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The three levels of inputs that may be used to measure fair value are as follows:
	Level 1 - quoted prices in active markets for identical assets or liabilities
	Level 2 - quoted prices for similar assets and liabilities in active markets or inputs that are observable
	Level 3 - inputs that are unobservable (for example cash flow modeling inputs based on assumptions)
	Warrant liabilities represent the only financial assets or liabilities recorded at fair value by the Company. The fair value of warrant liabilities are determined based on Level 3 inputs.
	Use of Estimates—The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make certain estimates and assumptions about the future outcome of current transactions which may affect the reporting and disclosure of these transactions. Accordingly, actual results could differ from those estimates used in the preparation of these consolidated financial statements.
	The following critical accounting policies affect the company’s more significant judgments and estimates used in the preparation of these financial statements:
	Stock-Based Compensation - Stock-based compensation expense is estimated as of the grant date based on the fair value of the award and is recognized as expense over the requisite service period, which generally equals the vesting period, based on the number of awards that are expected to vest. Estimating the fair value for stock options requires judgment, including the expected term of our stock options, volatility of the company’s stock, expected dividends, risk-free interest rates over the expected term of the options and the expected forfeiture rate. In connection with performance based programs, the company makes assumptions principally related to the number of awards that are expected to vest after assessing the probability that certain performance criteria will be met.
	Income Taxes - The Company accounts for federal and state income taxes under the liability method, with a deferred tax asset or liability determined based on the difference between the financial statement and tax basis of assets and liabilities, as measured by the enacted tax rates. The Company’s provision for income taxes represents the amount of taxes currently payable, if any, plus the change in the amount of net deferred tax assets or liabilities. A valuation allowance is provided against net deferred tax assets if recoverability is uncertain on a more likely than not basis. The Company recognizes in its consolidated financial statements the impact of an uncertain tax position if the position will more likely than not be sustained upon examination by a taxing authority, based on the technical merits of the position. The Company’s policy is to recognize interest related to unrecognized tax benefits as interest expense and penalties as operating expenses. The Company is not currently under examination by any taxing authority nor has it been notified of an impending examination. The Company’s tax returns for the years ended December 31, 2014, 2013 and 2012, remain open for possible review.
	Warrant liability - The fair value of warrant liability is estimated using the Binomial Lattice option valuation model.  The use of the Binomial Lattice option valuation model requires estimates including the volatility of the company’s stock, risk-free rates over the expected term of warrants and early exercise of the options.
	Basic and Diluted Net Loss per Common Share—Basic and diluted net loss per common share are computed based on the weighted average number of common shares outstanding. Common share equivalents (which consist of options and warrants) are excluded from the computation of diluted net loss per share for the years ended December 31, 2014, 2013 and 2012, since the effect would be antidilutive. Common share equivalents which could potentially dilute basic earnings per share in the future, and which were excluded from the computation of diluted net loss per share, totaled 19,420,978     , 26,108,984 and 24,139,760 shares at December 31, 2014, 2013 and 2012, respectively.
	Recently Issued Accounting Standards— In June 2014, the Financial Accounting Standards Board (FASB) issued ASU No. 2014-12, which removes the definition of a development stage entity from FASB ASC 915 and eliminates the disclosure requirements for development stage entities to 1) present inception-to-date information on the statements of operations, cash flows and shareholders’ equity; 2) label the financial statements as those of a development stage entity, 3) disclose a description of the development stage activities in which the entity is engaged and 4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been a development stage.  This ASU added a requirement for the entity to disclose its major risks and uncertainties.  The ASU is effective for annual reporting periods beginning after December 15, 2014; however, early adoption is permitted.  The Company decided to adopt this ASU effective in the second quarter of 2014.  The adoption of this ASU did not have a material impact on the Company’s consolidated results of operations, financial condition or liquidity.
	In August 2014, the FASB issued ASU No. 2014-15, which applies to entities that have substantial doubt about their ability to continue as a going concern.  This update requires management to assess the probability about the entity’s ability to remain as a going concern for a period of one year from the date the financial statements are ready to be issued.  Depending on management’s conclusions about the entity’s ability to remain as a going concern, the entity must make certain disclosures in its financial statements.  This ASU is effective for annual periods beginning after December 15, 2016.  The adoption of this is not expected to have a material impact on the Company’s consolidated results of operations, financial condition or liquidity.
	Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the Securities Exchange Commission (the SEC) did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.

Property_and_Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2014
Property Plant And Equipment [Abstract]
Property and Equipment	3	Property and Equipment
	Property and equipment consist of the following:
			December 31,			December 31,
			2014			2013
	Computers		$	59,076		$	67,566
	Research equipment			143,185			117,809
				202,261			185,375
	Accumulated depreciation			(154,896	)		(118,933	)
			$	47,365		$	66,442
	Depreciation expense was $47,656, $50,402 and $45,823 for the years ended December 31, 2014, 2013 and 2012, respectively.

RelatedParty_Transactions

Related-Party Transactions	12 Months Ended
	Dec. 31, 2014
Related Party Transactions [Abstract]
Related-Party Transactions	4	Related-Party Transactions
	Cedars-Sinai Medical Center License Agreement
	Dr. John Yu, our Chief Scientific Officer and former interim Chief Executive Officer, is a neurosurgeon at Cedars-Sinai Medical Center (Cedars-Sinai). In November 2006, the Company entered into a license agreement with Cedars-Sinai under which the Company acquired an exclusive, worldwide license to its technology for use as cellular therapies, including cancer stem cell and dendritic cell-based vaccines for neurological disorders that include brain tumors and neurodegenerative disorders and other cancers. This technology is covered by a number of pending U.S. and foreign patent applications, and the term of the license will be until the last to expire of any patents that are issued covering this technology.
	As an upfront licensing fee, the Company issued Cedars-Sinai 694,000 shares of its common stock and paid Cedars-Sinai $62,000. Additional specified milestone payments will be required to be paid to Cedars-Sinai when the Company initiates patient enrollment in its first Phase III clinical trial and when it receives FDA marketing approval for its first product.
	The Company has agreed to pay Cedars-Sinai specified percentages of all of its sublicensing income and gross revenues from sales of products based on the licensed technology. To maintain its rights to the licensed technology, the Company must meet certain development and funding milestones. These milestones include, among others, commencing a Phase I clinical trial for a product candidate by March 31, 2007 and raising at least $5,000,000 in funding from equity or other sources by December 31, 2008. The Company satisfied the foregoing funding requirement in 2007 and commenced a Phase I clinical trial in May 2007, which was within the applicable cure period for the milestone requirement. Through December 31, 2009, the Company has paid Cedars-Sinai a total of $166,660 in connection with the Phase I clinical trial. The Company also was required to commence a Phase II clinical trial for a product candidate by December 31, 2008 and a waiver of this requirement was obtained from Cedars-Sinai (see Second Amendment below).
	On June 16, 2008, the Company entered into a First Amendment to Exclusive License Agreement (the Amendment) with Cedars-Sinai. The Amendment amended the License Agreement to include in the Company’s exclusive license from Cedars-Sinai under that agreement an epitope to CD133 and certain related intellectual property. This technology is covered by U.S. patent applications filed by both parties. Pursuant to the Amendment, the Company issued Cedars-Sinai 100,000 shares of the Company’s common stock as an additional license fee for the licensed CD133 epitope technology, which will be subject to the royalty and other terms of the License Agreement.
	On July 22, 2009, the Company entered into a Second Amendment to Exclusive License Agreement (the Second Amendment) with Cedars-Sinai to become effective August 1, 2009. The Second Amendment amended the License Agreement to revise the milestones set forth in the License Agreement that the Company must achieve in order to maintain its license rights under that agreement. The revised milestones include the replacement of a milestone that required commencement of a Phase II clinical trial for the Company’s first product candidate by no later than December 31, 2008 with milestones that require commencement of a Phase I clinical trial for the Company’s second product candidate by no later than June 30, 2010 and commencement of a Phase II clinical trial for one of the Company’s product candidates by no later than March 31, 2012.
	Effective March 23, 2010, the Company entered into a Third Amendment to Exclusive License Agreement (the Third Amendment) with Cedars-Sinai. The Third Amendment amended the License Agreement to revise the milestones set forth in the License Agreement that the Company must achieve in order to maintain its license rights under that agreement. The revised milestones include the replacement of a milestone that required commencement of a Phase I clinical trial for the Company’s second product candidate by no later than June 30, 2010 and commencement of a Phase II clinical trial for one of the Company’s product candidates by no later than March 31, 2012 with a requirement that the Company by September 30, 2011 either commence a Phase II clinical trial for its dendritic cell vaccine candidate or a Phase I clinical trial for its cancer stem cell vaccine candidate. The amendment also added a requirement that the Company obtain certain defined forms of equity or other funding in the amount of at least $2,500,000 by December 31, 2010 and a total of at least $5,000,000 by September 30, 2011. These funding requirements were fully satisfied as of June 30, 2011.
	Effective September 20, 2010, the Company entered into a sponsored research agreement with Cedars-Sinai under which Cedars-Sinai provided services to the Company in developing the ICT-121 vaccine at a total cost of $446,142.  Effective September 20, 2011, the Company entered into Amendment No. 1 extending the agreement to September 19, 2012 at an incremental cost of $294,504.  Effective September 20, 2012, the Company entered into Amendment No. 2 extending the agreement to September 19, 2013 at an incremental cost of $329,832.  This agreement concluded on September 19, 2013 but was extended through March 19, 2014 at an incremental cost of $126,237.

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2014
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	5	Commitments and Contingencies
	Sponsored Research Agreements
	In an effort to expand the Company’s intellection property portfolio to use antigens to create personalized vaccines, the Company has entered into various intellectual property and research agreements. Those agreements are long-term in nature and are discussed below.
	Aptiv Solutions
	The Company has contracted with Aptiv Solutions to provide certain services related to the Company’s ICT-107 Phase II trial. The original agreement was entered into in August of 2010 and provided for estimated payments of approximately $3 million for services through September 2013. Subsequently, the Company and Aptiv entered into three contract amendments. Under the first amendment, effective January 20, 2011, Aptiv agreed to provide additional services in conjunction with the Phase II trial of ICT-107 for an additional fee of $469,807. The second amendment, effective February 4, 2012, extended the services to be provided by Aptiv and further increased the fees by $986,783. The second amendment also extended the term of the agreement to March 31, 2014. On January 11, 2013, the third amendment was finalized whereby the services were further extended and the fees were further increased by $608,201. The total aggregate fee pursuant to the original agreement and the three modifications is $5,078,169.
	On September 17, 2013, the Company entered into a Master Services Agreement with Aptiv Solutions to provide certain services related to the Company’s ICT-140 Phase II trial.  The related Project Agreement Number 1 entered into on September 17, 2013  provided for estimated payments of approximately $2.7 million until completion of the services described therein.  Currently, the Company has suspended development of ICT-140 as of December 31, 2014 and, therefore, there is no ongoing commitment related to this program.
	As of December 31, 2014, the Company’s remaining obligation under the existing commitments is approximately $2.0 million.
	The John Hopkins University Licensing Agreement
	On February 23, 2012, the Company entered into an Exclusive License Agreement, effective as of February 16, 2012, with The John Hopkins University (JHU) under which it received an exclusive, world-wide license to JHU’s rights in and to certain intellectual property related to mesothelin-specific cancer immunotherapies. The Company is advancing a cancer vaccine program using JHU and other intellectual property according to commercially reasonable development timeline.  If successful and a product ultimately is registered, the Company will either sell the product directly or via a third-party partnership.
	Pursuant to the License Agreement, the Company agreed to pay an upfront licensing fee in the low hundreds of thousands of dollars, payable half in cash and half in shares of its common stock in two tranches, within 30 days of the effective date of the License Agreement and upon issuance of the first U.S. patent covering the subject technology. Annual minimum royalties or maintenance fees increase over time and range from low tens of thousands to low hundreds of thousands of dollars. In addition, the Company has agreed to pay milestone license fees upon completion of specified milestones, totaling single digit millions of dollars if all milestones are met.  Royalties based on a low single digit percentage of net sales are also due on direct sales, while third party sublicensing payments will be shared at a low double digit percentage.
	The Company and JHU each have termination rights that include termination for any reason and for reasons relating to specific performance or financial conditions.   Effective September 24, 2013, the Company entered into an Amendment No. 1 to the Exclusive License Agreement that updated certain milestones.
	The University of Pittsburgh Patent License Agreement
	On March 20, 2012, the Company entered into an Exclusive License Agreement with the University of Pittsburgh under which the Company has licensed intellectual property surrounding EphA2, a tyrosine kinase receptor that is highly expressed by ovarian cancer and other advanced and metastatic malignancies. The License Agreement grants a world-wide exclusive license to the intellectual property for ovarian and pancreatic cancers; and a world-wide non-exclusive license to the intellectual property for brain cancer.
	Pursuant to the License Agreement, the Company agreed to pay an upfront nonrefundable and noncreditable licensing fee and nonrefundable and noncreditable maintenance fees due annually starting 12 months from the anniversary of the effective date of the License Agreement. In addition, the Company has agreed to make certain milestone payments upon completion of specified milestones and to pay customary royalties based on a specified percentage of net sales and sublicensing payments, as applicable.
	Torrey Pines
	On October 1, 2012, the Company entered into a Contract Services Agreement with Torrey Pines under which the Company has engaged Torrey Pines to determine the immunogenicity of certain peptides that are used in conjunction with the Company’s ICT-107 Phase II trial and in the development of ICT-140. The Company agreed to pay an upfront nonrefundable and noncreditable fee and is obligated to pay the remainder at the conclusion of the contract. On April 1, 2013, the Company and Torrey Pines expanded the scope of work to be completed by Torrey Pines under an additional Contract Services Agreement. This supplemental agreement provides for the Company to pay an upfront fee and additional fees at the conclusion of the contract.  On April 1, 2014, the Company and Torrey Pines entered into an Amended and Restated Contract Services Agreement for Torrey Pines to perform certain additional services in connection with the Company’s vaccine technologies.
	California Institute of Technology
	On September 9, 2014, the Company entered into an Exclusive License Agreement with the California Institute of Technology (Caltech) under which the Company acquired exclusive rights to novel technology for the development of certain stem cell treatments that are potentially capable of producing antigen specific T-cell killing of cancer cells.
	Pursuant to the License Agreement, the Company agreed to pay a one time license fee, a minimum annual royalty based on a low single digit percentage of net revenues and an annual maintenance fee in the low tens of thousands of dollars.  In addition, the Company has agreed to make certain milestone payments upon completion of specified milestones.
	Cedars-Sinai Medical Center
	In connection with the Cedars-Sinai Medical Center License Agreement, the Company has certain commitments as described in Note 4.
	Summary of Employment Agreements
	The Company has employment agreements with its management that provide for base salary, bonus, stock option grants and severance. The aggregate base salary payable to this group is approximately $1.0 million and the potential bonus is approximately $300,000.  During the years ended December 31, 2014, 2013 and 2012, the Company issued an aggregate of 317,500, 489,000 and 785,000 stock options to its management at a weighted average exercise price of $1.34, $2.66 and $2.25, respectively.  All of the aforementioned stock options vest over a period of 4 years.  Additionally, certain members of management are also entitled to severance payments in the event of a change in control or termination without cause.  The aggregate potential severance payments to management is approximately $728,000.  These members of management would also be entitled to COBRA for various periods of time.
	Operating Lease
	The Company entered into a lease for new office space effective June 15, 2013 and continuing through August 31, 2016 at an initial monthly rental of $8,063. The monthly rental increases by 3% on each anniversary date of the lease. Rent for the months of August and September 2013 was abated. Rent expense was approximately $99,000, $80,000 and $50,000 for the years ended December 31, 2014, 2013 and 2012, respectively.
	Future minimum rentals under the operating lease are as follows:
	Years ending December 31,		Amount
	2015		$	100,905
	2016			68,432
	Total		$	169,337
	Contractual Obligations
	The following is a summary of our contractual obligations including those entered into subsequent to December 31, 2014.
			Total		Less than		3-Jan		5-Mar		More than
					1 year		years		years		5 years
	Unconditional purchase obligations for		$	2,003,305	$	1,110,103	$	893,202	$	—	$	—
	research and development
	Operating lease obligation		$	169,337		100,905		68,432		—		—
			$	2,172,642	$	1,211,008	$	961,634	$	—	$	—

Shareholders_Equity

Shareholders' Equity	12 Months Ended
	Dec. 31, 2014
Equity [Abstract]
Shareholders Equity	6	Shareholders’ Equity
	Common Stock
	In February 2011, the Company raised $7,460,129 (after commissions and offering expenses) from the sale of 5,219,768 shares of common stock and warrants to purchase 2,609,898 shares of common stock at an exercise price of $2.25 per share, to various investors in a private placement. The warrants contain a provision whereby the warrant exercise price would be decreased in the event that certain future common stock issuances are made at a price less than $1.55. The January and October 2012 underwritten public offerings (see below) provided for the issuance of shares at prices that were less than $1.55. Accordingly, the exercise price of these warrants was adjusted to $1.87 and the number of warrants was proportionately increased to 2,823,696 net of exercises. (See “Warrants and Warrant Liabilities” below)
	In January 2012, the Company raised $9,271,370 in an underwritten public offering, net of offering expenses of approximately $1.1 million, from the sale of 9,489,436 shares of common stock and warrants to purchase 4,744,718 shares of common stock at an exercise price of $1.41 per share, to various investors in an underwritten public offering. The warrants have a term of 60 months from the date of issuance. The warrants do not contain any features (such as net cash settlement or anti-dilution features) that would preclude the Company from accounting for these warrants as equity. Accordingly, the warrants are accounted for as equity.
	In October 2012, the Company raised $19,359,553 in an underwritten public offering, net of offering expenses of approximately $1.6 million, from the sale of 10,000,000 shares of common stock and warrants to purchase 4,500,000 shares of common stock at an exercise price of $2.65 per share, to various investors in an underwritten public offering. The warrants have a term of 60 months from the date of issuance. The warrants do not contain any features (such as net cash settlement or anti-dilution features) that would preclude the Company from accounting for these warrants as equity. Accordingly, the warrants are accounted for as equity.
	See Subsequent Events (Note 10) for a description of the Company’s February 2015 underwritten public offering.
	Controlled Equity Offering
	On April 18, 2013, the Company entered into a Controlled Equity OfferingSM Sales Agreement (the Sales Agreement) with Cantor Fitzgerald & Co., as agent (Cantor), pursuant to which the Company may offer from time to time through Cantor, shares of our common stock having an aggregate offering price of up to $25.0 million (of which only $17.0 million is currently registered for offer and sale). Under the Sales Agreement, Cantor may sell shares by any method permitted by law and deemed to be an “at-the-market” offering as defined in Rule 415 promulgated under the Securities Act, as amended, including sales made directly on the NYSE MKT, on any other existing trading market for our common stock or to or through a market maker. The Company may instruct Cantor not to sell shares if the sales cannot be effected at or above the price designated by us from time to time. The Company is not obligated to make any sales of the shares under the Sales Agreement. The offering of shares pursuant to the Sales Agreement will terminate upon the earlier of (a) the sale of all of the shares subject to the Sales Agreement or (b) the termination of the Sales Agreement by Cantor or the Company, as permitted therein. Cantor will receive a commission rate of 3.0% of the aggregate gross proceeds from each sale of shares and the Company has agreed to provide Cantor with customary indemnification and contribution rights. The Company will also reimburse Cantor for certain specified expenses in connection with entering into the Sales Agreement. On April 22, 2013, NYSE MKT approved the listing of 10,593,220 shares of our common stock in connection with the Sales Agreement. Through December 31, 2014, we sold 6,946,261 shares of our common stock under the Sales Agreement that resulted in net proceeds to the Company of approximately $9,402,383. As of December 31, 2014, aggregate gross sales for additional common stock of approximately $7,081,494 remained available under the Sales Agreement.
	Stock Options
	In February 2005, the Company adopted an Equity Incentive Plan (Plan). Pursuant to the Plan, a committee appointed by the Board of Directors may grant, at its discretion, qualified or nonqualified stock options, stock appreciation rights and may grant or sell restricted stock to key individuals, including employees, nonemployee directors, consultants and advisors. Option prices for qualified incentive stock options (which may only be granted to employees) issued under the plan may not be less than 100% of the fair market value of the common stock on the date the option is granted (unless the option is granted to a person who, at the time of grant, owns more than 10% of the total combined voting power of all classes of stock of the Company; in which case the option price may not be less than 110% of the fair market value of the common stock on the date the option is granted). Option prices for nonqualified stock options issued under the Plan are at the discretion of the committee and may be equal to, greater or less than fair market value of the common stock on the date the option is granted. The options vest over periods determined by the Board of Directors and are exercisable no later than ten years from date of grant (unless they are qualified incentive stock options granted to a person owning more than 10% of the total combined voting power of all classes of stock of the Company, in which case the options are exercisable no later than five years from date of grant). Initially, the Company reserved 6,000,000 shares of common stock for issuance under the Plan. On October 24, 2011, the Company’s shareholders voted to increase the number of authorized shares reserved for the Plan to 8,000,000 shares. On September 20, 2013, the Company’s shareholders voted to increase the number of authorized shares reserved for the Plan to 12,000,000 shares. Options to purchase 3,231,340 common shares have been granted under the Plan and are outstanding as of December 31, 2014.  As of December 31, 2014, there were 5,835,731 options available for issuance under the Plan.
	The following is a summary of stock option grants issued outside the Plan:
	In January 2007, the Company granted an option to purchase 1,500,000 shares of its common stock at an exercise price of $1.10 per share to the Chairman of the Company’s Scientific Advisory Board.
	In November 2006, the Company granted an option to purchase 300,000 shares of its common stock at an exercise price of $1.00 per share to an affiliate of the Company’s then Chairman of the Board.
	In November 2006, the Company granted an option to purchase 5,933,424 shares of its common stock at an exercise price of $1.00 per share to a Board member in connection with the Cedars-Sinai license acquisition.
	The following table summarizes stock option activity for the Company during the three years ended December 31, 2014:
						Weighted			Weighted
						Average			Average			Aggregate
						Exercise			Contractual			Intrinsic
			Options			Price			Term			Value
	Outstanding December 31, 2011			10,774,078		$	1.07
	Granted			1,292,500		$	2.5
	Exercised			(1,285,384	)	$	0.95
	Forfeited or expired			(200,000	)	$	2.25
	Outstanding December 31, 2012			10,581,194		$	1.16
	Granted			862,287		$	2.67
	Exercised			(829,702	)	$	0.92
	Forfeited or expired			(147,084	)	$	1.81
	Outstanding December 31, 2013			10,466,695		$	1.37
	Granted			547,117		$	1.28
	Exercised			(624,047	)	$	2.36
	Forfeited or expired			(1,075,000	)	$	1.08
	Outstanding December 31, 2014			9,314,765		$	1.33			2.94		$	23,000
				7,923,353		$	1.19			2.38		$	23,000
	Vested or expected to vest at December 31, 2014
	As of December 31, 2014, the total unrecognized compensation cost related to unvested stock options amounted to $1,622,889, which will be amortized over the weighted-average remaining requisite service period of approximately 16 months.
	Warrants
	In connection with the May 2010 common stock private placement, the Company issued to the investors warrants to purchase 1,245,455 shares of the Company’s common stock at $1.50 per share. The warrants have a term of 36 months from the date of issuance. As of December 31, 2014 these warrants have been fully exercised, except for warrants to purchase 4,000 shares of the Company’s common stock that expired. (see “Warrant Liability” below)
	In connection with the sale of Preferred Stock in May 2010, the Company issued warrants to purchase 1,350,000 shares of common stock at an exercise price of $2.50. The warrants have a term of five-years from the date of issuance. As of December 31, 2014, warrants to purchase 1,290,996 shares of the Company’s common stock at $2.50 were outstanding related to this private placement. (See “Warrant Liability” below.)
	In connection with the February 2011 common stock private placement, the Company issued to the investors warrants to purchase 2,818,675 shares of the Company’s common stock at $2.25 per share. The warrants have a five-year term from the date of issuance and contain a provision that provides for an adjustment to the exercise price in the event the Company completes an equity financing at a per share price of its common stock that is less than the adjusted exercise price. As a result of the January and October 2012 financings, the exercise price of the warrants was adjusted to $1.87 and the number of warrants was proportionately increased to 2,823,670 net of exercises. During 2014, the exercise price was further adjusted to $1.79 and the number of warrants was proportionately increased to 2,949,867 net of exercises to reflect the issuances pursuant to the Company’s Controlled Equity OfferingSM.   As of December 31, 2014, warrants to purchase 2,949,867 shares of the Company’s common stock were outstanding related to this private placement. (See “Warrant Liability” below.)
	In connection with the January 2012 underwritten public offering, the Company issued to the investors warrants to purchase 4,744,718 shares of the Company’s common stock at $1.41 per share. The warrants have a five-year term from the date of issuance. These warrants qualify for equity treatment since they do not have any provisions that would require the Company to redeem them for cash or that would result in an adjustment to the number of warrants. As of December 31, 2014, warrants to purchase 1,418,575 shares of the Company’s common stock remain outstanding relating to this public offering.
	In connection with the October 2012 underwritten public offering, the Company issued to the investors warrants to purchase 4,500,000 shares of the Company’s common stock at $2.65 per share. The warrants have a five-year term from the date of issuance. These warrants qualify for equity treatment since they do not have any provisions that would require the Company to redeem them for cash or that would result in an adjustment to the number of warrants. As of December 31, 2014, warrants to purchase 4,446,775 shares of the Company’s common stock remain outstanding relating to this public offering.
	Warrant Liability
	The Company’s warrant liability is adjusted to fair value each reporting period and is influenced by several factors including the price of the Company’s common stock as of the balance sheet date. On December 31, 2014, the price per share of Company’s common stock was $0.73 per share compared to $0.93 per share at December 31, 2013 and $1.92 per share at December 31, 2012.
	In connection with the March 2010 common stock private placement, the Company issued to the investors warrants to purchase 696,000 shares of the Company’s common stock at $1.15 per share. Of the total proceeds from the March 2010 common stock private placement, $257,520 was allocated to the freestanding warrants associated with the units based upon the fair value of the warrants determined under the Black Scholes option pricing model. The warrants contain a provision whereby the warrant exercise price would be decreased in the event that future common stock issuances are made at a price less than $1.00. Due to the potential variability of their exercise price, these warrants do not qualify for equity treatment, and therefore are recognized as a liability. The warrant liability was adjusted to fair value each reporting period, and any change in value is recognized in the statement of operations. Prior to 2011, the Company had concluded that Black-Scholes method of valuing the price adjustment feature does not materially differ from the valuation of such warrants using the lattice simulation model, and therefore, the use of the Black-Scholes valuation model was considered a reasonable method to value the warrants. The assumptions used in the Black Scholes model for determining the initial fair value of the warrants were as follows: (i) dividend yield of 0%; (ii) expected volatility of 102%, (iii) risk-free interest rate of 1.00%, and (iv) contractual life of 26 months. During the year ended December 31, 2011, the Company determined that it was more appropriate to value the warrants using a binomial lattice simulation model. During 2012, the remaining warrants were fully exercised; however, the Company recorded a charge to other expense of $745,500 as the Company revalued the warrants through the date of exercise.
	In connection with the May 2010 common stock private placement, the Company issued to the investors warrants to purchase 1,245,455 shares of the Company’s common stock at $1.50 per share. Of the total proceeds from the May 2010 common stock private placement, $834,455 was allocated to the freestanding warrants associated with the units based upon the fair value of the warrants determined under the Black Scholes option pricing model. The warrants contain a provision whereby the warrant exercise price would be decreased in the event that future common stock issuances are made at a price less than $1.00. Due to the potential variability of their exercise price, these warrants do not qualify for equity treatment, and therefore are recognized as a liability. The warrant liability is adjusted to fair value each reporting period, and any change in value is recognized in the statement of operations. Prior to 2011, the Company concluded that the Black-Scholes method of valuing the price adjustment feature does not materially differ from the valuation of such warrants using the binomial lattice simulation models, and therefore, the use of the Black-Scholes valuation model was considered a reasonable method to value the warrants. The assumptions used in the Black Scholes model for determining the initial fair value of the warrants were as follows: (i) dividend yield of 0%; (ii) expected volatility of 102%, (iii) risk-free interest rate of 1.375%, and (iv) contractual life of 36 months. Effective January 1, 2011 the Company determined that it was more appropriate to value the warrants using a binomial lattice simulation model. During 2013, the remaining warrants were fully exercised; however, the Company recorded a charge to other expense of $583,134 as the Company revalued the warrants through the date of exercise.
	In connection with the sale of Preferred Stock in 2010, the Company vested warrants to purchase 1,350,000 shares of the Company’s common stock at an exercise price of $2.50 per share. Of the total proceeds from the May 2010 preferred stock sale, $5,710,500 was allocated to the freestanding warrants associated with the units based upon the fair value of these warrants determined under the Black Scholes option pricing model. The warrants contain a provision whereby the warrant may be settled for cash in connection with a change of control with a private company. Due to their potential cash settlement, these warrants do not qualify for equity treatment, and therefore are recognized as a liability. The warrant liability is adjusted to fair value each reporting period and any change in value is recognized in the statement of operations. Prior to 2011, the Company concluded that the Black-Scholes method of valuing the price adjustment feature does not materially differ from the valuation of such warrants using the Monte Carlo or binomial lattice simulation models, and therefore, the use of the Black-Scholes valuation model was considered a reasonable method to value the warrants. The assumptions used in the Black Scholes model for determining the initial fair value of the warrants were as follows: (i) dividend yield of 0%; (ii) expected volatility of 102%, (iii) risk-free interest rate of 2.50%, and (iv) contractual life of 60 months. Effective January 1, 2011, the Company determined that it was more appropriate to value the warrants using a binomial lattice simulation model. The lattice simulation model used by the Company at December 31, 2013, assumed (i) dividend yield of 0%; (ii) expected volatility of 123%; (iii) risk free rate of 0.21% and (iv) expected term of 1.34 years. For the year ended December 31, 2013, the Company recorded a credit to other expense of $320,167. As of December 31, 2014, the Company revalued the warrants using the binomial lattice simulation model assuming (i) dividend yield of 0%; (ii) expected volatility of 106%; (iii) risk free rate of 0.04% and (iv) expected term of 0.34 years.  For the year ended December 31, 2014, the Company recorded a credit to other expense of $260,781.  As of December 31, 2014, the carrying value of the warrant liability is $7,746.
	In connection with the February 2011 common stock private placement, the Company issued to the investors warrants to purchase 2,818,675 shares of the Company’s common stock at $2.25 per share. Of the total proceeds from the February 2011 common stock private placement, $2,476,790 was allocated to the freestanding warrants associated with the units based upon the fair value of the warrants determined under the Binomial lattice model. The warrants contain a provision whereby the warrant exercise price would be decreased in the event that certain future common stock issuances are made at a price less than $1.55. Due to the potential variability of their exercise price, these warrants do not qualify for equity treatment, and therefore are recognized as a liability. As a result of the January and October 2012 financings, the exercise price of the warrants was adjusted to $1.87 and the number of warrants was proportionately increased to 2,823,696 net of exercises. The Company recorded a charge to financing expense of $397,294 to reflect the issuance of the additional warrants. As a result of the Company’s Controlled Equity OfferingSM during 2014, the exercise price of the warrants was adjusted to $1.79 and the number of warrants was proportionately increased to 2,949,867, net of exercises. The Company recorded a charge to financing expense of $62,683 to reflect the issuance of the additional warrants. The warrant liability is adjusted to fair value each reporting period, and any change in value is recognized in the statement of operations. The Company initially valued these warrants using a binomial lattice simulation model assuming (i) dividend yield of 0%; (ii) expected volatility of 146%; (iii) risk free rate of 1.96% and (iv) expected term of 5 years. Based upon those calculations, the Company calculated the initial valuation of the warrants to be $2,476,790. The lattice simulation model used by the Company at December 31, 2013assumed (i) dividend yield of 0%; (ii) expected volatility of 111%; (iii) risk free rate of 0.44% and (iv) expected term of 2.14 years. For the year ended December 31, 2013, the Company recorded a credit to other expense of $905,377. As of December 31, 2014, the Company revalued the warrants using the binomial lattice simulation model assuming (i) dividend yield of 0%; (ii) expected volatility of 148%; (iii) risk free rate of 0.31% and (iv) expected term of 1.14 years.  For the year ended December 31, 2014, the Company recorded a credit to other expense of $268,993.  As of December 31, 2014, the carrying value of the warrant liability is $589,973. The exercise price of these warrants will be adjusted in conjunction with the Company’s February 2015 underwritten public offering.  See Subsequent Events (Note 10).
	The below table summarizes the warrant liability activity for the years ended December 31, 2014, 2013 and 2012. The loss included in earnings is reflective of several factors including the increase in the Company’s stock during the years ended December 31, 2014, 2013 and 2012.
			2014			2013			2012
	Beginning Balance, January 1		$	1,064,810		$	2,852,880		$	2,157,408
	Issuance of warrants and effect of repricing			62,683			—			397,294
	Exercise of warrants			—			(1,145,659	)		(1,981,745
	(Gain) or loss included in earnings			(529,774	)		(642,411	)		2,279,923	)
	Transfers in and/or out of Level 3			—			—			—
	Ending Balance, December 31		$	597,719		$	1,064,810		$	2,852,880

401K_Profit_Sharing_Plan

401(K) Profit Sharing Plan	12 Months Ended
	Dec. 31, 2014
Compensation And Retirement Disclosure [Abstract]
401(k) Profit Sharing Plan	7	401(k) Profit Sharing Plan
	During 2011, the Company adopted a Profit Sharing Plan that qualifies under Section 401(k) of the Internal Revenue Code. Contributions to the plan are at the Company’s discretion. The Company did not make any matching contributions during the years ended December 31, 2014 and 2013.

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Taxes	8	Income Taxes
	Deferred taxes represent the net tax effects of the temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes. Temporary differences result primarily from the recording of tax benefits of net operating loss carry forwards and stock-based compensation.
	As of December 31, 2014, the Company has an insufficient history to support the likelihood of ultimate realization of the benefit associated with the deferred tax asset. Accordingly, a valuation allowance has been established for the full amount of the net deferred tax asset.
	The Company’s effective income tax rate differs from the amount computed by applying the federal statutory income tax rate to loss before income taxes as follows:
			2014			2013			2012
	Income tax benefit at the federal statutory rate			34	%		-34	%		-34	%
	State income tax benefit, net of federal tax benefit			6	%		-6	%		-6	%
	Change in fair value of warrant liability			-13	%		-3	%		-6	%
	Change in valuation allowance for deferred tax assets			-27	%		43	%		46	%
	Total			0	%		0	%		0	%
	Deferred taxes consisted of the following:
			December 31,			December 31,
			2014			2013
	Net operating loss carryforwards		$	16,302,000		$	15,759,274
	Stock-based compensation			2,191,000			2,020,987
	Less valuation allowance			(18,493,000	)		(17,780,261	)
	Net deferred tax asset		$	—		$	—
	As of December 31, 2014, the Company had federal and California income tax net operating loss carryforwards of approximately $40.8 million. These net operating losses will begin to expire in 2022 and 2016, respectively, unless previously utilized.
	Section 382 of the Internal Revenue Code can limit the amount of net operating losses which may be utilized if certain changes to a company’s ownership occur. While the Company underwent an ownership change in 2012 as defined by Section 382 of the Internal Revenue Code, management estimated that the Company has not incurred any limitations on its ability to utilize its net operating losses under Section 382 of the Internal Revenue Code during 2013. The Company has not determined whether an ownership change has occurred as a result of the Company’s issuance of common stock in February 2015 (see Subsequent Events Note 10) and consequently, has not determined if it will incur any limitations on its ability to utilize its net operation losses under Section 382.
	During the fourth quarter of 2014, the Company licensed the non-U.S. rights to a significant portion of its intellectual property to its Bermuda-based subsidiary for approximately $11.0 million. The fair value of the intellectual property rights was determined by an independent third party. The proceeds from this sale represent a gain for U.S. tax purposes and are offset by current year losses and net operating loss carryforwards. However, the Internal Revenue Service, or the IRS, or the California Franchise Tax Board, or the CFTB, could challenge the valuation of the intellectual property rights and assess a greater valuation, which would require the Company to utilize a portion, or all, of its available net operating losses. If an IRS or a CFTB valuation exceeds the available net operating losses, the Company would incur additional income taxes. The Company’s ability to use its net operating losses is subject to the limitations of IRS Section 382, as well as expiration of federal and state net operating loss carryforwards.

Supplementary_Financial_Inform

Supplementary Financial Information	12 Months Ended
	Dec. 31, 2014
Quarterly Financial Information Disclosure [Abstract]
Supplementary Financial Information	9	Supplementary Financial Information
	Summary of Quarterly Results (Unaudited)
			Quarter Ended
			March			June			September			December			Fiscal Year
	Fiscal 2014
	Revenues		$	—		$	—		$	—		$	—		$	—
	Net income (loss)			(3,161,977	)		(2,199,140	)		(1,889,243	)		(2,127,173	)		(9,377,533	)
	Net income (loss) per common share
	Basic		$	(0.05	)	$	(0.04	)	$	(0.03	)	$	(0.03	)	$	(0.16	)
	Diluted		$	(0.05	)	$	(0.04	)	$	(0.03	)	$	(0.03	)	$	(0.16	)
	Fiscal 2013
	Revenues		$	—		$	—		$	—		$	—		$	—
	Net income (loss)			(4,973,791	)		(150,329	)		(3,793,441	)		116,998			(8,800,563	)
	Net income (loss) per common share
	Basic		$	(0.10	)	$	0		$	(0.07	)	$	0		$	(0.16	)
	Diluted		$	(0.10	)	$	0		$	(0.07	)	$	0		$	(0.16	)

Subsequent_Events

Subsequent Events	12 Months Ended
	Dec. 31, 2014
Subsequent Events [Abstract]
Subsequent Events	10	Subsequent Events
	Underwritten Public Offering
	On February 12, 2015, we entered into an underwriting agreement with Roth Capital Partners, LLC, pursuant to which we sold 26,650,000 shares of our common stock and warrants to purchase 18,655,000 shares of our common stock at a combined offering price of $0.60 per share and accompanying warrant to purchase 0.70 of a share of our common stock. The resulting aggregate net proceeds from the offering was approximately $14.6 million, after deducting underwriting discounts and other offering expenses payable by us of approximately $1.4 million. The warrants have an exercise price of $0.66 per share and a term of 60 months from the date of issuance. The warrants also provide for a weighted-average adjustment to the exercise price if we issue or are deemed to issue additional shares of our common stock at a price per share less than the then effective exercise price of the warrants, subject to certain exceptions. Accordingly, these warrants will be accounted for as derivative liabilities.  The Company has not finalized the accounting for these warrants.  The warrants that were issued in February 2011 included provisions whereby the exercise price and the number of warrants would be adjusted if there was a subsequent financing that included a per share price that was less than $1.79.  The Company has not finalized the adjustment to the exercise price of these warrants as the adjustment is dependent on the valuation of the warrants that were issued as part of the February 2015 financing.
	Stock Option Grants
	The Company’s Board of Directors approved the granting of 418,000 stock options to certain officers and employees on March 6, 2015. These options have an exercise price equal to the closing stock price on March 6, 2015 of $0.59, with 50,000 stock options vesting immediately and the remainder vesting over a period of four years.

Valuation_and_Qualifying_Accou

Valuation and Qualifying Accounts	12 Months Ended
	Dec. 31, 2014
Valuation And Qualifying Accounts [Abstract]
Valuation and Qualifying Accounts	IMMUNOCELLULAR THERAPEUTICS, LTD.
	Schedule II - Valuation and Qualifying Accounts
		Additions
		Beginning		Charged to		Other	Deductions	Ending
		Balance		Costs &		Amounts		Balance
				Expenses
	2014
	Deferred Tax Asset Valuation Account	$	17,780,261	$	712,739			$	18,493,000
	2013
	Deferred Tax Asset Valuation Account	$	14,618,703	$	3,161,558			$	17,780,261
	2012
	Deferred Tax Asset Valuation Account	$	11,004,790	$	3,613,913			$	14,618,703

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2014
Principles of Consolidation	Principles of Consolidation – The accompanying consolidated financial statements include the accounts of the Company and its subsidiaries.  All significant intercompany balances and transactions have been eliminated in consolidation.
Liquidity	Liquidity —As of December 31, 2014, the Company had working capital of $23,152,970, compared to working capital of $27,007,377 as of December 31, 2013. The estimated cost of completing the development of any of our current vaccine product candidates and of obtaining all required regulatory approvals to market any of those product candidates is substantially greater than the amount of funds we currently have available. However, we believe that our existing cash balances are sufficient for our currently planned level of operations for at least the next twelve months from the date of filing of this Annual Report on Form 10-K, although there is no assurance that such proceeds will be sufficient for this purpose.
Cash and cash equivalents	Cash and cash equivalents—The Company considers all highly liquid instruments with an original maturity of 90 days or less when purchased to be cash equivalents. As of December 31, 2014 and December 31, 2013, the Company had $10,427,810      and $25,913,893, respectively, of certificates of deposit. The Company places its cash and cash equivalents with various banks in order to maintain FDIC insurance on all of its investments.
Property and Equipment	Property and Equipment—Property and equipment are stated at cost and depreciated using the straight-line methods based on the estimated useful lives (generally three to five years) of the related assets. Computer and computer equipment are depreciated over three years. Management continuously monitors and evaluates the realizability of recorded long-lived assets to determine whether their carrying values have been impaired. The Company records impairment losses on long-lived assets used in operations when events and circumstances indicate that the assets might be impaired and the nondiscounted cash flows estimated to be generated by those assets are less than the carrying amount of those assets. Any impairment loss is measured by comparing the fair value of the asset to its carrying amount. Repairs and maintenance costs are expensed as incurred.
Research and Development Expenses	Research and Development Expenses—Research and development expenses consist of costs incurred for direct research and development and are expensed as incurred
Stock Based Compensation	Stock Based Compensation—The Company records the cost for all share-based payment transactions in the Company’s consolidated financial statements.
	Fair value was estimated at the date of grant using the following assumptions:
		Year			Year			Year
		Ended			Ended			Ended
		December 31,			December 31,			December 31,
		2014			2013			2012
	Risk-free interest rate		2.18	%		1.64	%		0,49	%
	Expected dividend yield		None			None			None
	Expected life		5.47 years			5.21 years			4.40 years
	Expected volatility		95.3	%		90.58	%		66.1	%
	Expected forfeitures		0	%		0	%		0	%
	The weighted-average grant-date fair value of options granted during the year ended December 31, 2014, 2013 and 2012 was $0.96     , $1.89 and $1.29, respectively.
	The risk-free interest rate used is based on the implied yield currently available in U.S. Treasury securities at maturity with an equivalent term. The Company has not declared or paid any dividends and does not currently expect to do so in the future. The expected term of options represents the period that our stock-based awards are expected to be outstanding and was determined based on projected holding periods for the remaining unexercised shares. Consideration was given to the contractual terms of our stock-based awards, vesting schedules and expectations of future employee behavior. For the year ended December 31, 2014, the expected volatility is based upon the historical volatility of the Company’s common stock. Forfeitures have been estimated to be nil.
	The Company’s stock price volatility and option lives involve management’s best estimates, both of which impact the fair value of the option calculated and, ultimately, the expense that will be recognized over the life of the option.
	When options are exercised, our policy is to issue previously unissued shares of common stock to satisfy share option exercises. As of December 31, 2014, the Company had 56,491,509      shares of authorized but unissued common stock. As of December 31, 2014, the Company had 5,835,731 shares of common stock reserved for its stock option plan.
	No tax benefits were attributed to the stock-based compensation expense because a valuation allowance was maintained for all net deferred tax assets.
Income Taxes	Income Taxes—The Company accounts for federal and state income taxes under the liability method, with a deferred tax asset or liability determined based on the difference between the financial statement and tax basis of assets and liabilities, as measured by the enacted tax rates. The Company’s provision for income taxes represents the amount of taxes currently payable, if any, plus the change in the amount of net deferred tax assets or liabilities. A valuation allowance is provided against net deferred tax assets if recoverability is uncertain on a more likely than not basis. As of December 31, 2014 and 2013, the Company fully reserved its deferred tax assets. The Company recognizes in its consolidated financial statements the impact of an uncertain tax position if the position will more likely than not be sustained upon examination by a taxing authority, based on the technical merits of the position. The Company’s policy is to recognize interest related to unrecognized tax benefits as interest expense and penalties as operating expenses. As of December 31, 2014, the Company had no unrecognized tax benefits and as such, no liability, interest or penalties were required to be recorded.  The Company does not expect this to change significantly in the next twelve months.  The Company has determined that its main taxing jurisdictions are the United States of America and the State of California.  The Company is not currently under examination by any taxing authority nor has it been notified of a pending examination. The Company’s tax returns are generally no longer subject to examination for the years before December 31, 2010 for the state and December 31, 2011 for the federal taxing authority.
	During the fourth quarter of 2014, the Company licensed the non-U.S. rights to a significant portion of its intellectual property to its Bermuda-based subsidiary for approximately $11.0 million. The fair value of the intellectual property rights was determined by an independent third party. The proceeds from this sale represent a gain for U.S. tax purposes and are offset by current year losses and net operating loss carryforwards. However, the Internal Revenue Service, or the IRS, or the California Franchise Tax Board, or the CFTB, could challenge the valuation of the intellectual property rights and assess a greater valuation, which would require the Company to utilize a portion, or all, of its available net operating losses. If an IRS or a CFTB valuation exceeds the available net operating losses, the Company would incur additional income taxes. The Company’s ability to use its net operating losses is subject to the limitations of IRS Section 382, as well as expiration of federal and state net operating loss carryforwards.
Fair Value of Financial Instruments	Fair Value of Financial Instruments—The carrying amounts reported in the balance sheets for cash, cash equivalents, and accounts payable approximate their fair values due to their quick turnover. The fair value of warrant liability is estimated using the Binomial Lattice option valuation model.
	Fair value for financial reporting is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.  The Company utilizes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The three levels of inputs that may be used to measure fair value are as follows:
	Level 1 - quoted prices in active markets for identical assets or liabilities
	Level 2 - quoted prices for similar assets and liabilities in active markets or inputs that are observable
	Level 3 - inputs that are unobservable (for example cash flow modeling inputs based on assumptions)
	Warrant liabilities represent the only financial assets or liabilities recorded at fair value by the Company. The fair value of warrant liabilities are determined based on Level 3 inputs.
Use of Estimates	Use of Estimates—The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make certain estimates and assumptions about the future outcome of current transactions which may affect the reporting and disclosure of these transactions. Accordingly, actual results could differ from those estimates used in the preparation of these consolidated financial statements.
Warrant Liability	Warrant liability - The fair value of warrant liability is estimated using the Binomial Lattice option valuation model.  The use of the Binomial Lattice option valuation model requires estimates including the volatility of the company’s stock, risk-free rates over the expected term of warrants and early exercise of the options.
Basic and Diluted Net Loss per Common Share	Basic and Diluted Net Loss per Common Share—Basic and diluted net loss per common share are computed based on the weighted average number of common shares outstanding. Common share equivalents (which consist of options and warrants) are excluded from the computation of diluted net loss per share for the years ended December 31, 2014, 2013 and 2012, since the effect would be antidilutive. Common share equivalents which could potentially dilute basic earnings per share in the future, and which were excluded from the computation of diluted net loss per share, totaled 19,420,978     , 26,108,984 and 24,139,760 shares at December 31, 2014, 2013 and 2012, respectively.
Recently Issued Accounting Standards	Recently Issued Accounting Standards— In June 2014, the Financial Accounting Standards Board (FASB) issued ASU No. 2014-12, which removes the definition of a development stage entity from FASB ASC 915 and eliminates the disclosure requirements for development stage entities to 1) present inception-to-date information on the statements of operations, cash flows and shareholders’ equity; 2) label the financial statements as those of a development stage entity, 3) disclose a description of the development stage activities in which the entity is engaged and 4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been a development stage.  This ASU added a requirement for the entity to disclose its major risks and uncertainties.  The ASU is effective for annual reporting periods beginning after December 15, 2014; however, early adoption is permitted.  The Company decided to adopt this ASU effective in the second quarter of 2014.  The adoption of this ASU did not have a material impact on the Company’s consolidated results of operations, financial condition or liquidity.
	In August 2014, the FASB issued ASU No. 2014-15, which applies to entities that have substantial doubt about their ability to continue as a going concern.  This update requires management to assess the probability about the entity’s ability to remain as a going concern for a period of one year from the date the financial statements are ready to be issued.  Depending on management’s conclusions about the entity’s ability to remain as a going concern, the entity must make certain disclosures in its financial statements.  This ASU is effective for annual periods beginning after December 15, 2016.  The adoption of this is not expected to have a material impact on the Company’s consolidated results of operations, financial condition or liquidity.
	Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the Securities Exchange Commission (the SEC) did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.
Critical Accounting Policies
Stock Based Compensation	Stock-Based Compensation - Stock-based compensation expense is estimated as of the grant date based on the fair value of the award and is recognized as expense over the requisite service period, which generally equals the vesting period, based on the number of awards that are expected to vest. Estimating the fair value for stock options requires judgment, including the expected term of our stock options, volatility of the company’s stock, expected dividends, risk-free interest rates over the expected term of the options and the expected forfeiture rate. In connection with performance based programs, the company makes assumptions principally related to the number of awards that are expected to vest after assessing the probability that certain performance criteria will be met.
Income Taxes	Income Taxes - The Company accounts for federal and state income taxes under the liability method, with a deferred tax asset or liability determined based on the difference between the financial statement and tax basis of assets and liabilities, as measured by the enacted tax rates. The Company’s provision for income taxes represents the amount of taxes currently payable, if any, plus the change in the amount of net deferred tax assets or liabilities. A valuation allowance is provided against net deferred tax assets if recoverability is uncertain on a more likely than not basis. The Company recognizes in its consolidated financial statements the impact of an uncertain tax position if the position will more likely than not be sustained upon examination by a taxing authority, based on the technical merits of the position. The Company’s policy is to recognize interest related to unrecognized tax benefits as interest expense and penalties as operating expenses. The Company is not currently under examination by any taxing authority nor has it been notified of an impending examination. The Company’s tax returns for the years ended December 31, 2014, 2013 and 2012, remain open for possible review.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Schedule of Stock Options Grants	Fair value was estimated at the date of grant using the following assumptions:
		Year			Year			Year
		Ended			Ended			Ended
		December 31,			December 31,			December 31,
		2014			2013			2012
	Risk-free interest rate		2.18	%		1.64	%		0,49	%
	Expected dividend yield		None			None			None
	Expected life		5.47 years			5.21 years			4.40 years
	Expected volatility		95.3	%		90.58	%		66.1	%
	Expected forfeitures		0	%		0	%		0	%

Property_and_Equipment_Tables

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2014
Property Plant And Equipment [Abstract]
Components of Property and Equipment	Property and equipment consist of the following:
		December 31,			December 31,
		2014			2013
	Computers	$	59,076		$	67,566
	Research equipment		143,185			117,809
			202,261			185,375
	Accumulated depreciation		(154,896	)		(118,933	)
		$	47,365		$	66,442

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2014
Commitments And Contingencies Disclosure [Abstract]
Future Minimum Rentals Under Operating Lease	Future minimum rentals under the operating lease are as follows:
	Years ending December 31,	Amount
	2015	$	100,905
	2016		68,432
	Total	$	169,337
Summary of Contractual Obligations	The following is a summary of our contractual obligations including those entered into subsequent to December 31, 2014.
		Total		Less than		3-Jan		5-Mar		More than
				1 year		years		years		5 years
	Unconditional purchase obligations for	$	2,003,305	$	1,110,103	$	893,202	$	—	$	—
	research and development
	Operating lease obligation	$	169,337		100,905		68,432		—		—
		$	2,172,642	$	1,211,008	$	961,634	$	—	$	—

Shareholders_Equity_Tables

Shareholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2014
Equity [Abstract]
Summary of Stock Options Activity	The following table summarizes stock option activity for the Company during the three years ended December 31, 2014:
					Weighted			Weighted
					Average			Average			Aggregate
					Exercise			Contractual			Intrinsic
		Options			Price			Term			Value
	Outstanding December 31, 2011		10,774,078		$	1.07
	Granted		1,292,500		$	2.5
	Exercised		(1,285,384	)	$	0.95
	Forfeited or expired		(200,000	)	$	2.25
	Outstanding December 31, 2012		10,581,194		$	1.16
	Granted		862,287		$	2.67
	Exercised		(829,702	)	$	0.92
	Forfeited or expired		(147,084	)	$	1.81
	Outstanding December 31, 2013		10,466,695		$	1.37
	Granted		547,117		$	1.28
	Exercised		(624,047	)	$	2.36
	Forfeited or expired		(1,075,000	)	$	1.08
	Outstanding December 31, 2014		9,314,765		$	1.33			2.94		$	23,000
			7,923,353		$	1.19			2.38		$	23,000
	Vested or expected to vest at December 31, 2014
Summary of Carrying Value of Warrant Liability	The below table summarizes the warrant liability activity for the years ended December 31, 2014, 2013 and 2012. The loss included in earnings is reflective of several factors including the increase in the Company’s stock during the years ended December 31, 2014, 2013 and 2012.
		2014			2013			2012
	Beginning Balance, January 1	$	1,064,810		$	2,852,880		$	2,157,408
	Issuance of warrants and effect of repricing		62,683			—			397,294
	Exercise of warrants		—			(1,145,659	)		(1,981,745
	(Gain) or loss included in earnings		(529,774	)		(642,411	)		2,279,923	)
	Transfers in and/or out of Level 3		—			—			—
	Ending Balance, December 31	$	597,719		$	1,064,810		$	2,852,880

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Federal Statutory Income Tax Rate to Loss before Income Taxes	The Company’s effective income tax rate differs from the amount computed by applying the federal statutory income tax rate to loss before income taxes as follows:
		2014			2013			2012
	Income tax benefit at the federal statutory rate		34	%		-34	%		-34	%
	State income tax benefit, net of federal tax benefit		6	%		-6	%		-6	%
	Change in fair value of warrant liability		-13	%		-3	%		-6	%
	Change in valuation allowance for deferred tax assets		-27	%		43	%		46	%
	Total		0	%		0	%		0	%
Deferred Tax Asset	Deferred taxes consisted of the following:
		December 31,			December 31,
		2014			2013
	Net operating loss carryforwards	$	16,302,000		$	15,759,274
	Stock-based compensation		2,191,000			2,020,987
	Less valuation allowance		(18,493,000	)		(17,780,261	)
	Net deferred tax asset	$	—		$	—

Supplementary_Financial_Inform1

Supplementary Financial Information (Tables)	12 Months Ended
	Dec. 31, 2014
Quarterly Financial Information Disclosure [Abstract]
Summary of Quarterly Results (Unaudited)
		Quarter Ended
		March			June			September			December			Fiscal Year
	Fiscal 2014
	Revenues	$	—		$	—		$	—		$	—		$	—
	Net income (loss)		(3,161,977	)		(2,199,140	)		(1,889,243	)		(2,127,173	)		(9,377,533	)
	Net income (loss) per common share
	Basic	$	(0.05	)	$	(0.04	)	$	(0.03	)	$	(0.03	)	$	(0.16	)
	Diluted	$	(0.05	)	$	(0.04	)	$	(0.03	)	$	(0.03	)	$	(0.16	)
	Fiscal 2013
	Revenues	$	—		$	—		$	—		$	—		$	—
	Net income (loss)		(4,973,791	)		(150,329	)		(3,793,441	)		116,998			(8,800,563	)
	Net income (loss) per common share
	Basic	$	(0.10	)	$	0		$	(0.07	)	$	0		$	(0.16	)
	Diluted	$	(0.10	)	$	0		$	(0.07	)	$	0		$	(0.16	)

Nature_of_Organization_Planned1

Nature of Organization (Planned Principal Operations Have Not Commenced) (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Deficit accumulated during the development stage	($61,346,926)	($51,969,393)

Summary_of_Significant_Account3

Summary of Significant Accounting Policies - Additional Information (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Disclosure Summary Of Significant Accounting Policies Additional Information Detail [Line Items]
Working capital	$23,152,970	$27,007,377
Certificates of deposit	10,427,810	25,913,893
Weighted-average grant-date fair value of options granted	$0.96	$1.89	$1.29
Shares authorized but unissued common stock	56,491,509
Common stock reserved	5,835,731
Tax benefit attributed to the stock-based compensation expense	0	0	0
Unrecognized Tax Benefits	0
Unrecognized Tax Benefits, liability, Penalties or Interest Accrued	0
Fair value of the intellectual property	$11,000,000
Shares excluded from the computation of diluted net loss per share	19,420,978	26,108,984	24,139,760
Minimum
Disclosure Summary Of Significant Accounting Policies Additional Information Detail [Line Items]
Estimated useful lives of property and equipment	3 years
Maximum
Disclosure Summary Of Significant Accounting Policies Additional Information Detail [Line Items]
Estimated useful lives of property and equipment	5 years
Computer Equipment
Disclosure Summary Of Significant Accounting Policies Additional Information Detail [Line Items]
Estimated useful lives of property and equipment	3 years

Summary_of_Significant_Account4

Summary of Significant Accounting Policies (Details)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Schedule of stock options grants
Risk-free interest rate	2.18%	1.64%	49.00%
Expected dividend yield	0.00%	0.00%	0.00%
Expected life	5 years 5 months 19 days	5 years 2 months 16 days	4 years 4 months 24 days
Expected volatility	95.30%	90.58%	66.10%
Expected forfeitures	0.00%	0.00%	0.00%

Property_and_Equipment_Details

Property and Equipment (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Components of Property and Equipment
Property and equipment, gross	$202,261	$185,375
Accumulated depreciation	-154,896	-118,933
Property and equipment, net	47,365	66,442
Computer Equipment
Components of Property and Equipment
Property and equipment, gross	59,076	67,566
Research Equipment
Components of Property and Equipment
Property and equipment, gross	$143,185	$117,809

Property_and_Equipment_Additio

Property and Equipment - Additional Information (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Property Plant And Equipment [Abstract]
Depreciation expense	$47,656	$50,402	$45,823

Related_Party_Transactions_Det

Related Party Transactions (Details Textual) (Cedars-Sinai Medical Center License Agreement, USD $)	0 Months Ended			1 Months Ended	32 Months Ended	0 Months Ended
	Sep. 19, 2013	Sep. 20, 2012	Sep. 20, 2010	Nov. 30, 2006	Dec. 31, 2009	Sep. 20, 2011	Sep. 30, 2011	Dec. 31, 2010	Dec. 31, 2008	Jun. 16, 2008
Related Party Transaction [Line Items]
Common stock, shares issued				694,000
Payment for upfront licensing fee				$62,000
Funding from equity									5,000,000
Payment to related Party					166,660
Shares issued to related parties										100,000
Other funding to related parties							5,000,000	2,500,000
Expected final contract price	126,237	329,832	446,142
Amendment No. 1
Related Party Transaction [Line Items]
Expected final contract price						$294,504

Commitments_and_Contingencies_1

Commitments and Contingencies - Additional Information (Details) (USD $)	12 Months Ended			0 Months Ended			38 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Jan. 11, 2013	Feb. 04, 2012	Jan. 20, 2011	Sep. 30, 2013	Sep. 17, 2013
Commitments And Contingencies [Line Items]
Extended agreement date	31-Mar-14
Nonrefundable And Noncreditable License And Maintenance Fee	12 months
Discretionary cash bonus	$0	$0
Options, granted	547,117	862,287	1,292,500
Exercise option price	$1.28	$2.67	$2.50
Stock options, vesting period	4 years
Lease monthly rent	8,063
Operating lease rent expense	99,000	80,000	50,000
Percentage of annual increase of monthly base rent	3.00%
JHU
Commitments And Contingencies [Line Items]
Period within effective date of License Agreement	30 days
Employment Agreement With Management
Commitments And Contingencies [Line Items]
Base salary	1,000,000
Discretionary cash bonus	300,000
Options, granted	317,500	489,000	785,000
Exercise option price	$1.34	$2.66	$2.25
Stock options, vesting period	4 years
Severance costs	728,000
Aptiv Solution
Commitments And Contingencies [Line Items]
Payments for services	3,000,000
Number of contract amendments	3
Service fee, amendments and aggregate				608,201	986,783	469,807	5,078,169
Estimated payments for services								2,700,000
Company's remaining commitment obligation	$2,000,000

Commitments_and_Contingencies_2

Commitments and Contingencies - Future Minimum Rentals Under Operating Lease (Details) (USD $)	Dec. 31, 2014
Future Minimum Rentals Under the Operating Lease
2015	$100,905
2016	68,432
Operating lease obligation total	$169,337

Commitments_and_Contingencies_3

Commitments and Contingencies - Summary of Contractual Obligations (Details) (USD $)	Dec. 31, 2014
Commitments And Contingencies Disclosure [Abstract]
Unconditional purchase obligations for research and development total	$2,003,305
Unconditional purchase obligations for research and development less than one year	1,110,103
Unconditional purchase obligations for research and development one to three years	893,202
Operating lease obligation total	169,337
Operating lease obligation less than year	100,905
Operating lease obligation one to three years	68,432
Total	2,172,642
less than one year	1,211,008
One to three years	$961,634

Shareholders_Equity_Details_Te

Shareholders' Equity (Details Textual) (USD $)

0 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

Apr. 22, 2013

Apr. 18, 2013

Oct. 31, 2012

Jan. 31, 2012

Feb. 28, 2011

31-May-10

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2010

Jan. 31, 2007

Nov. 30, 2006

Mar. 31, 2010

Dec. 31, 2011

31-May-13

Sep. 20, 2013

Oct. 24, 2011

Feb. 28, 2005

Class Of Stock [Line Items]

Proceeds from the common stock private placement

$19,359,553

$9,271,370

$7,460,129

$834,455

Sale of common stock and warrants , shares

10,000,000

9,489,436

5,219,768

Number of warrants outstanding increased net of exercises

2,823,670

2,823,696

2,949,867

Public offering expenses

1,600,000

1,100,000

Exercise price of warrants

$2.65

Common stock aggregate offering price

6,360

5,754

Commission rate

3.00%

Listing of shares of common stock in connection with Sales Agreement

10,593,220

Percentage of fair market value of common stock

not be less than 100%

Percentage of common stock voting rights held

more than 10%

Minimum percentage of fair market value of common stock

less than 110%

Maximum exercisable period of options

10 years

Maximum exercisable period of options if percentage of common stock voting rights held is more than ten percent

5 years

Common stock, shares authorized under the plan

12,000,000

8,000,000

6,000,000

Common stock, shares granted and outstanding

9,314,765

10,466,695

10,581,194

10,774,078

Stock options available for issuance

5,835,731

Purchase of common stock, shares

4,744,718

Exercise option price

$1.28

$2.67

$2.50

Options, Granted

547,117

862,287

1,292,500

Unrecognized compensation cost related to unvested stock options

1,622,889

Weighted-average remaining requisite service period

16 months

Common stock, price per share

$1.41

$0.73

$0.93

$1.92

Common Stock Shares Purchased Private Placement Warrant

2,823,696

2,949,867

Warrants exercisable period after initial issuance

5 years

5 years

5 years

Adjusted exercise price of warrants

$1.87

$1.87

$1.79

Contractual life

26 months

Financing expense

62,683

397,294

Warranty Obligations

Class Of Stock [Line Items]

Common Stock Shares Purchased Private Placement Warrant

2,949,867

Adjusted exercise price of warrants

$1.79

Chairman Of Companys Scientific Advisory Board

Class Of Stock [Line Items]

Purchase of common stock, shares

1,500,000

Exercise option price

$1.10

Affiliate Of Chairman

Class Of Stock [Line Items]

Exercise option price

$1

Options, Granted

300,000

Board

Class Of Stock [Line Items]

Exercise option price

$1

Options, Granted

5,933,424

Stock Compensation Plan

Class Of Stock [Line Items]

Common stock, shares granted and outstanding

3,231,340

Cantor Fitzgerald & Co.

Class Of Stock [Line Items]

Common stock issued through controlled equity offering, shares

6,946,261

Proceeds from Issuance of common stock

9,402,383

Additional common stock sales gross

7,081,494

Cantor Fitzgerald & Co. | Offer and Sale

Class Of Stock [Line Items]

Common stock aggregate offering price

17,000,000

Warrant

Class Of Stock [Line Items]

Warrant exercise term investor relations agreement

60 months

60 months

Purchase of common stock, shares

696,000

Common stock, price per share

$1.15

Common Stock Warrants Expired

4,000

Dividend yield rate

0.00%

Expected volatility rate

102.00%

Risk-free interest rate

1.00%

February

Class Of Stock [Line Items]

Proceeds from the common stock private placement

2,476,790

Warrant liability carrying value

589,973

February | Binomial Lattice Simulation

Class Of Stock [Line Items]

Dividend yield rate

0.00%

0.00%

Expected volatility rate

148.00%

111.00%

Risk-free interest rate

0.31%

0.44%

Contractual life

1 year 1 month 21 days

2 years 1 month 21 days

Credit to other expense

268,993

905,377

February | Binomial Simulation | Previous Valuation Assumptions

Class Of Stock [Line Items]

Dividend yield rate

0.00%

Expected volatility rate

146.00%

Risk-free interest rate

1.96%

Contractual life

5 years

Initial valuation of warrants

2,476,790

February | Warrant

Class Of Stock [Line Items]

Purchase of common stock, shares

2,818,675

Common stock, price per share

$2.25

May

Class Of Stock [Line Items]

Warrant Exercise Term Private Placement

36 months

Dividend yield rate

0.00%

Expected volatility rate

102.00%

Risk-free interest rate

1.38%

Contractual life

36 months

Change in fair value of warrant liability credited to other income

583,134

May | Warranty Obligations

Class Of Stock [Line Items]

Purchase of common stock, shares

1,245,455

Common stock, price per share

$1.50

May | Warrant

Class Of Stock [Line Items]

Purchase of common stock, shares

1,245,455

Common stock, price per share

$1.50

May | Preferred Stock

Class Of Stock [Line Items]

Purchase of common stock, shares

1,350,000

Common stock, price per share

$2.50

$2.50

Common Stock Shares Purchased Private Placement Warrant

1,290,996

Proceeds from warrant shares attributed to free standing warrants related party of investor

5,710,500

Warrant liability carrying value

7,746

May | Preferred Stock | Binomial Lattice Simulation

Class Of Stock [Line Items]

Dividend yield rate

0.00%

0.00%

Expected volatility rate

106.00%

123.00%

Risk-free interest rate

0.04%

0.21%

Contractual life

4 months 2 days

1 year 4 months 2 days

Credit to other expense

260,781

320,167

May | Preferred Stock | Binomial Simulation

Class Of Stock [Line Items]

Dividend yield rate

0.00%

Expected volatility rate

102.00%

Risk-free interest rate

2.50%

Contractual life

60 months

January

Class Of Stock [Line Items]

Common Stock Shares Purchased Private Placement Warrant

1,418,575

October

Class Of Stock [Line Items]

Exercise price of warrants

$2.65

Purchase of common stock, shares

4,500,000

Common Stock Shares Purchased Private Placement Warrant

4,446,775

Warrants exercisable period after initial issuance

5 years

March

Class Of Stock [Line Items]

Proceeds from the common stock private placement

257,520

March | Binomial Lattice Simulation

Class Of Stock [Line Items]

Change in fair value of warrant liability credited to other income

745,500

Maximum | Warranty Obligations

Class Of Stock [Line Items]

Common stock, price per share

$1

Maximum | Cantor Fitzgerald & Co.

Class Of Stock [Line Items]

Common stock aggregate offering price

25,000,000

Maximum | Warrant

Class Of Stock [Line Items]

Common stock, price per share

$1

Maximum | February

Class Of Stock [Line Items]

Common stock, price per share

$1.55

Shareholders_Equity_Details

Shareholders' Equity (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Summary of stock option activity
Options outstanding, Beginning Balance	10,466,695	10,581,194	10,774,078
Options, Granted	547,117	862,287	1,292,500
Options, Exercised	-624,047	-829,702	-1,285,384
Options, Forfeited or expired	-1,075,000	-147,084	-200,000
Options outstanding, Ending Balance	9,314,765	10,466,695	10,581,194
Options, Vested or expected to vest	7,923,353
Weighted Average Exercise Price, Outstanding, Beginning Balance	$1.37	$1.16	$1.07
Exercise option price	$1.28	$2.67	$2.50
Weighted Average Exercise Price, Exercised	$2.36	$0.92	$0.95
Weighted Average Exercise Price, Forfeited or expired	$1.08	$1.81	$2.25
Weighted Average Exercise Price, Outstanding, Ending Balance	$1.33	$1.37	$1.16
Weighted Average Exercise Price, Vested or expected to vest	$1.19
Weighted Average Contractual Term, Outstanding	2 years 11 months 9 days
Weighted Average Contractual Term, Vested or expected to vest	2 years 4 months 17 days
Aggregate Intrinsic Value, Outstanding	$23,000
Aggregate Intrinsic Value, Vested or expected to vest	$23,000

Shareholders_Equity_Details_1

Shareholders' Equity (Details 1) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Summary of carrying value of warrant liability
Beginning Balance, January 1	$1,064,810	$2,852,880	$2,157,408
Issuance of warrants and effect of repricing	62,683		397,294
Exercise of warrants		-1,145,659	-1,981,745
(Gain) or loss included in earnings	-529,774	-642,411	-2,279,923
Ending Balance, December 31	$597,719	$1,064,810	$2,852,880

401k_Profit_Sharing_Plan_Detai

401(k) Profit Sharing Plan (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Compensation And Retirement Disclosure [Abstract]
Discretionary cash bonus	$0	$0

Income_Taxes_Details

Income Taxes (Details)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Federal statutory income tax rate to loss before income taxes
Income tax benefit at the federal statutory rate	34.00%	-34.00%	-34.00%
State income tax benefit, net of federal tax benefit	6.00%	-6.00%	-6.00%
Change in fair value of warrant liability	-13.00%	-3.00%	-6.00%
Change in valuation allowance for deferred tax assets	-27.00%	43.00%	46.00%
Total	0.00%	0.00%	0.00%

Income_Taxes_Details_1

Income Taxes (Details 1) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Deferred Tax Asset
Net operating loss carryforwards	$16,302,000	$15,759,274
Stock-based compensation	2,191,000	2,020,987
Less valuation allowance	($18,493,000)	($17,780,261)

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Details) (USD $)	3 Months Ended	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2014
Income Taxes [Line Items]
Net operating losses expiration date		expire in 2022 and 2016
Proceed from licensing intellectual property	$11
Federal
Income Taxes [Line Items]
Income tax net operating loss carryforwards	40.8	40.8
California
Income Taxes [Line Items]
Income tax net operating loss carryforwards	$40.80	40.8

Supplementary_Financial_Inform2

Supplementary Financial Information (Details) (USD $)	3 Months Ended								12 Months Ended
	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Quarterly Financial Information Disclosure [Abstract]
Net income (loss)	($2,127,173)	($1,889,243)	($2,199,140)	($3,161,977)	$116,998	($3,793,441)	($150,329)	($4,973,791)	($9,377,533)	($8,800,563)	($14,495,139)
Net income (loss) per common share
Basic	($0.03)	($0.03)	($0.04)	($0.05)	$0	($0.07)	$0	($0.10)	($0.16)	($0.16)
Diluted	($0.03)	($0.03)	($0.04)	($0.05)	$0	($0.07)	$0	($0.10)	($0.16)	($0.16)

Subsequent_Events_Details

Subsequent Events (Details) (USD $)	1 Months Ended		12 Months Ended			0 Months Ended
	Oct. 31, 2012	Jan. 31, 2012	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Mar. 06, 2015	Feb. 12, 2015
Subsequent Event [Line Items]
Warrants to purchase common stock ratio			0.7
Adjusted exercise price of warrants	$1.87	$1.87	$1.79
Stock options available for issuance			5,835,731
Exercise within term of the option			4 years
Exercise option price			$1.28	$2.67	$2.50
Options, Vested or expected to vest			7,923,353
Subsequent Event
Subsequent Event [Line Items]
Common stock issued through controlled equity offering, shares							26,650,000
Common stock issued through controlled equity offering average, per share							$0.60
Proceeds from Issuance of common stock							$14,600,000
Underwriting discounts and other offering expenses							$1,400,000
Exercise price of warrants							$0.66
Warrants Expiration Term							60 months
Adjusted exercise price of warrants							$1.79
Stock options available for issuance						418,000
Exercise option price						$0.59
Options, Vested or expected to vest						50,000
Subsequent Event | Warrant
Subsequent Event [Line Items]
Common stock issued through controlled equity offering, shares							18,655,000

Valuation_and_Qualifying_Accou1

Valuation and Qualifying Accounts (Details) (Deferred Tax Asset Valuation Account, USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Deferred Tax Asset Valuation Account
Valuation And Qualifying Accounts Disclosure [Line Items]
Beginning Balance	$17,780,261	$14,618,703	$11,004,790
Charged to Costs & Expenses	712,739	3,161,558	3,613,913
Ending Balance	$18,493,000	$17,780,261	$14,618,703